Trial Profile
REBECCA: A Cohort Study of Regorafenib in the Real-life Setting in Patients Previously Treated for Metastatic Colorectal Cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms REBECCA
- 08 Aug 2016 Status changed from active, no longer recruiting to completed.
- 07 Nov 2014 New trial record
- 26 Sep 2014 Status changed from recruiting to active, no longer recruiting according to the abstract presented at the European Society for Medical Oncology 2014 Congress.